Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKAG1 | P54619 | 8/20 | 0.66 |
| ▸ | PRKAA1 | Q13131 | 8/20 | 0.66 |
| ▸ | PRKAB1 | Q9Y478 | 8/20 | 0.66 |
| ▸ | PRKAB2 | O43741 | 7/20 | 0.63 |
| ▸ | PRKAA2 | P54646 | 7/20 | 0.63 |
| ▸ | PRKAG3 | Q9UGI9 | 7/20 | 0.63 |
| ▸ | PRKAG2 | Q9UGJ0 | 7/20 | 0.63 |
| ▸ | FLT3 | P36888 | 2/20 | 0.49 |
| ▸ | CDK2 | P24941 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | CASP3 | P42574 | 1/20 | 0.47 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.47 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.47 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.46 |
| ▸ | BCHE | P06276 | 1/20 | 0.46 |
| ▸ | ACHE | P22303 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL929332 | 0.88 | PRKAG1 (0.79) | PRKAG1PRKAA1PRKAB1PRKAB2PRKAA2 | |
| SCHEMBL18554248 | 0.88 | BCHE (0.56) | PRKAG1PRKAA1PRKAB1PRKAB2PRKAA2 | |
| SCHEMBL16516393 | 0.86 | KDM4E (0.63) | PRKAG1PRKAA1PRKAB1PRKAB2PRKAA2 | |
| SCHEMBL13069602 | 0.86 | JAK2 (0.51) | PRKAG1PRKAA1PRKAB1PRKAB2PRKAA2 | |
| SCHEMBL10073863 | 0.84 | CYP1A2 (0.50) | PRKAG1PRKAA1PRKAB1PRKAB2PRKAA2 | |
| SCHEMBL3953836 | 0.84 | FLT3 (0.49) | PRKAG1PRKAA1PRKAB1PRKAB2PRKAA2 | |
| SCHEMBL12583303 | 0.84 | YTHDC1 (0.60) | PRKAG1PRKAA1PRKAB1PRKAB2PRKAA2 | |
| SCHEMBL4012655 | 0.84 | PRKAG1 (0.48) | PRKAG1PRKAA1PRKAB1PRKAB2PRKAA2 | |
| SCHEMBL3953831 | 0.82 | PRKAG1 (0.47) | PRKAG1PRKAA1PRKAB1PRKAB2PRKAA2 | |
| SCHEMBL11170339 | 0.82 | PRKAG1 (0.56) | PRKAG1PRKAA1PRKAB1PRKAB2PRKAA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1828179-B1 | NICOTINIC ALPHA-7 RECEPTOR LIGANDS AGAINST CNS-RELATED DISEASES | MEMORY PHARM CORP (US) | 2010-01-20 | — | — | EP | claimed |
| EP-3154974-B1 | TRICYCLIC COMPOUNDS AS ALPHA- 7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | BRISTOL MYERS SQUIBB CO (US) | 2018-11-14 | — | — | EP | disclosed |
| EP-2534151-B1 | 8-METHYL-1-PHENYL-IMIDAZOL[1,5-A]PYRAZINE COMPOUNDS | MERCK SHARP & DOHME (NL) | 2018-11-14 | — | — | EP | disclosed |
| US-9796713-B2 | Tricyclic compounds as alpha-7 nicotinic acetylcholine receptor ligands | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-10-24 | — | — | US | disclosed |
| US-20170129892-A1 | TRICYCLIC COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | BRISTOL MYERS SQUIBB CO (US) | 2017-05-11 | — | — | US | disclosed |
| EP-3154974-A1 | TRICYCLIC COMPOUNDS AS ALPHA- 7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | Bristol-Myers Squibb Company (US) | 2017-04-19 | — | — | EP | disclosed |
| EP-2742040-B1 | INDAZOLE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | HOFFMANN LA ROCHE (CH) | 2016-04-06 | — | — | EP | disclosed |
| WO-2015191401-A1 | TRICYCLIC COMPOUNDS AS ALPHA- 7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-12-17 | — | — | WO | disclosed |
| US-20140309210-A1 | INDAZOLE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2014-10-16 | — | — | US | disclosed |
| EP-2742040-A1 | INDAZOLE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | F.HOFFMANN-LA ROCHE AG (CH) | 2014-06-18 | — | — | EP | disclosed |
| WO-2006069097-A2 | NICOTINIC ALPHA-7 RECEPTOR LIGANDS AND PREPARATION AND USES THEREOF | MEMORY PHARMACEUTICALS CORPORATION (US) | 2006-06-29 | — | — | WO | disclosed |
| EP-1648867-A1 | PPAR ACTIVE COMPOUNDS | PLEXXIKON, INC. (US) | 2006-04-26 | — | — | EP | disclosed |
| US-20060014756-A1 | Benzimidazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2006-01-19 | — | — | US | disclosed |
| US-20050288354-A1 | PPAR active compounds | PLEXXIKON, INC. | 2005-12-29 | — | — | US | disclosed |
| US-6897208-B2 | Benzimidazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2005-05-24 | — | — | US | disclosed |
| US-20050038246-A1 | PPAR active compounds | PLEXXIKON, INC. | 2005-02-17 | — | — | US | disclosed |
| WO-2005009958-A1 | PPAR ACTIVE COMPOUNDS | PLEXXIKON, INC. (US) | 2005-02-03 | — | — | WO | disclosed |
| EP-1441725-A1 | BENZIMIDAZOLES AND ANALOGUES AND THEIR USE AS PROTEIN KINASES INHIBITORS | Aventis Pharmaceuticals Inc. (US) | 2004-08-04 | — | — | EP | disclosed |
| US-20040048868-A1 | Benzimidazoles | AVENTISUB LLC | 2004-03-11 | — | — | US | disclosed |
| WO-2003035065-A1 | BENZIMIDAZOLES AND ANALOGUES AND THEIR USE AS PROTEIN KINASES INHIBITORS | AVENTIS PHARMACEUTICALS INC (US) | 2003-05-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014756-A1 | Benzimidazoles | CDK9, BMX, SBK3 | PRKAG1 744/4885PRKAA1 365/4885PRKAB1 741/4885 |
| US-20050038246-A1 | PPAR active compounds | PPARG, PPARD, PPARA | PRKAG1 133/4885PRKAA1 139/4885PRKAB1 185/4885 |
| US-20140309210-A1 | INDAZOLE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | CYP3A43, INSR, CYP2C19 | PRKAG1 3725/4885PRKAA1 3585/4885PRKAB1 3821/4885 |
| US-20040048868-A1 | Benzimidazoles | CDK9, BMX, CDKN1A | PRKAG1 712/4885PRKAA1 386/4885PRKAB1 664/4885 |
| US-20170129892-A1 | TRICYCLIC COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | CHRNA7, CHRNA6, CHRNA5 | PRKAG1 1663/4885PRKAA1 2111/4885PRKAB1 1979/4885 |
| US-20050288354-A1 | PPAR active compounds | PPARG, PPARD, PPARA | PRKAG1 133/4885PRKAA1 139/4885PRKAB1 185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.